Mohit Narang

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation

Nanocarriers as an emerging platform for cancer therapy

Inflammation and tumor progression: signaling pathways and targeted intervention

TET enzymes, TDG and the dynamics of DNA demethylation

Therapy with azanucleosides for myelodysplastic syndromes

Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura

Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee

Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal

A review of the current use of rituximab in autoimmune diseases

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

Refractory autoimmune thrombocytopenic purpura: Responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab)

A Study Comparing Dosing Regimens and Efficacy of Subcutaneous to Intravenous Azacitidine (AZA) for the Treatment of Myelodysplastic Syndromes (MDS).